ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO109

Plasma Neutrophil Gelatinase Associated Lipocalin (NGAL) and the Prediction of Sustained AKI and Worsening Renal Function in Hospitalized Kidney Transplant Recipients

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Swolinsky, Jutta Sybille, Charité-Universitätsmedizin, Berlin, Germany
  • Hinz, Ricarda Merle, Charité-Universitätsmedizin, Berlin, Germany
  • Markus, Carolin Elfriede, Charité-Universitätsmedizin, Berlin, Germany
  • Singer, Eugenia, Charité-Universitätsmedizin, Berlin, Germany
  • Budde, Klemens, Charité-Universitätsmedizin, Berlin, Germany
  • Eckardt, Kai-Uwe, Charité-Universitätsmedizin, Berlin, Germany
  • Westhoff, Timm H., Ruhr Universität Bochum, Bochum, Germany
  • Schmidt-Ott, Kai M., Charité-Universitätsmedizin, Berlin, Germany
Background

Neutrophil gelatinase-associated lipocalin (NGAL) and Calprotectin (CPT) have been validated as biomarkers of acute kidney injury (AKI) in multiple clinical settings. The utility of these biomarkers in post-transplant care of kidney transplant recipients (KTR) remains largely unclear. We hypothesized that NGAL and CPT levels, measured at the time of any unscheduled hospital admission after kidney transplantation, would be associated with episodes of sustained AKI (sAKI) and worsening renal function (WRF).

Methods

As part of a monocentric cohort study of 709 KTR, plasma and urinary NGAL and CPT levels were measured in 164 KTR at the time of hospital admission for any non-elective cause. sAKI was defined as an increase in creatinine by ≥0.3 mg/dl or by ≥1.5-fold compared to outpatient baseline that did not normalize within 72 hours (h). WRF was defined as an increase in creatinine by ≥0.5 mg/dl within 72 h after admission. ROC analyses, univariable and multivariable logistic regression analyses and net reclassification improvement (NRI) were assessed for the biomarkers in predicting sAKI and WRF.

Results

33 KTR developed sAKI, 12 developed WRF. Plasma NGAL (pNGAL) had the highest diagnostic accuracy compared to urinary NGAL, urinary and plasma CPT. Median pNGAL levels at admission were significantly higher in patients with sAKI (332 [IQR 247.5-633] ng/ml versus no sAKI 275 [IQR 193-363] ng/ml, p<0.05) and WRF (395 [IQR 305-639] ng/ml versus no WRF 278.5 [IQR 193.5-378.8] ng/ml, p<0.05). ROC analyses for pNGAL showed an AUC ROC of 0.66 for sAKI and of 0.75 for WRF. A pNGAL level >410 ng/ml had positive likelihood ratios of 2.3 (95% CI 1.38-3.81) for sAKI and of 2.0 (95% CI 1.15-4.1) for WRF. In multivariable logistic regression, pNGAL was an independent predictor of sAKI when combined with other predictors (serum creatinine, coronary artery disease, congestive heart failure, p<0.05). Adding pNGAL to conventional predictors of sAKI resulted in an NRI of 20.5% (p<0.01).

Conclusion

Elevated pNGAL at the time of hospital admission may be useful in identifying KTR at risk of sustained or progressive acute kidney injury. Although test characteristics speak against its use as a single biomarker, it may contribute to prognostication.

Funding

  • Private Foundation Support